Compare ZETA & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZETA | ALKS |
|---|---|---|
| Founded | 2007 | 1987 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.8B |
| IPO Year | 2021 | 1991 |
| Metric | ZETA | ALKS |
|---|---|---|
| Price | $17.86 | $28.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | $26.25 | ★ $42.85 |
| AVG Volume (30 Days) | ★ 5.3M | 2.1M |
| Earning Date | 11-04-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2.44 |
| EPS | N/A | ★ 2.02 |
| Revenue | $1,224,703,000.00 | ★ $1,521,338,000.00 |
| Revenue This Year | $30.55 | N/A |
| Revenue Next Year | $30.24 | $24.22 |
| P/E Ratio | ★ N/A | $14.13 |
| Revenue Growth | ★ 35.87 | 1.08 |
| 52 Week Low | $10.69 | $25.17 |
| 52 Week High | $26.60 | $36.45 |
| Indicator | ZETA | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 44.94 | 40.53 |
| Support Level | $18.88 | $27.81 |
| Resistance Level | $19.96 | $29.35 |
| Average True Range (ATR) | 0.78 | 0.91 |
| MACD | 0.06 | -0.05 |
| Stochastic Oscillator | 19.84 | 11.75 |
Zeta Global Holdings Corp is an omnichannel data-driven cloud platform that provides enterprises with consumer intelligence and marketing automation software. It serves enterprise customers across multiple industries, including financial services, insurance, telecommunications, automotive, travel and hospitality, and retail. Its Zeta Marketing Platform, or ZMP, is an omnichannel marketing platform with identity data at its core. The ZMP can analyze billions of structured and unstructured data points to predict consumer intent by leveraging sophisticated machine learning algorithms and the industry's opted-in data set for omnichannel marketing.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.